Trusted by researchers and scientists worldwide, our cells are consistently cited in research publications, attesting their quality and dependability. We offer iPSC reprogramming, Cas9 genome editing, directed differentiation, custom cell isolation, in vitro assays, and ASO screening services. Our team of PhD scientists provides disease-relevant, patent-derived models that accelerate drug discovery and disease understanding. We specialize in complex assay development and execution for research support. Our expertise includes multi-cellular model building, 3D liver model signaling studies, and compound screening for iPSC-derived neurons and human immune cells.
San Diego, United States
Founded in 2014
11-50 Employees
Working industry
Biotechnology
Type of company
Manufacturer, Service provider
Ownership structure
Privately Held
Locations
1 Headquarter
Number of products
10 Products
Number of services
6 Services
Specialised areas
Personalized Medicine, ASO Screening, Professional, Scientific, and Technical Services, Immunoassays, Preclinical CRO services, Biotechnology, Induced Pluripotent Stem Cells, iPSC, Immuno-oncology, Patient-derived iPSC Generation
iXCells Biotechnologies offers a wide range of products and services
Product
Growth Factors & Cytokines - Cell Model Expert | iPSC | Primary Cells
Go to product >
Service
Genome Editing - Cell Model Expert | iPSC | Primary Cells
Go to product >
Product
Animal Primary Cells - Cell Model Expert | iPSC | Primary Cells
Go to product >
Product
iPSC & iPSC-derived Cells - Cell Model Expert | iPSC | Primary Cells
Go to product >
Service
Custom Immune Cell Isolation - Cell Model Expert | iPSC | Primary Cells
Go to product >
Product
Cell Media & Reagents - Cell Model Expert | iPSC | Primary Cells
Go to product >
Service
iPS Cell Generation - Cell Model Expert | iPSC | Primary Cells
Go to product >
Service
Custom Primary Cell Isolation - Cell Model Expert | iPSC | Primary Cells
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Get insights into the use cases of iXCells Biotechnologies
Use case
Applications - Cell Model Expert | iPSC | Primary Cells
Applications | Cell Based Assays | Immune Assays | Neuronal Assays | Disease Model Development | Antisense Oligonucleotide Screening | Information | Customer Service | My Account | Search Our Products | Shopping Cart
Use case
Antisense Oligonucleotide Screening - Cell Model Expert | iPSC | Primary Cells
ANTISENSE OLIGONUCLEOTIDE (ASO) SCREENING SERVICES | Case Study Individualized ASO Drug Development | ASO Screening Using Patient-Derived Cell Model | Integrated Drug Discovery Services with Patient-Specific Disease Models for N-of-1 Solution | SOME OF OUR CLIENTS & PARTNERS | THE RIGHT EXPERTISE TO SUPPORT YOUR PRECLINICAL DRUG DEVELOPMENT | Cell Model Development | RNA Therapeutics | Patient Centricity | Information Exchange | Information | Customer Service | My Account | Search Our Products | Shopping Cart
iXCells Biotechnologies operates in 1 country around the world
Get an overview of the locations of iXCells Biotechnologies
Location
Country
State
City
Headquarter
United States
California
San Diego
Some frequent questions that have been asked about iXCells Biotechnologies
Where is iXCells Biotechnologies located?
The company headquarter of iXCells Biotechnologies is located in San Diego, California, United States. It's worth noting, that the company may have more locations
How many employees does iXCells Biotechnologies approximately have?
As of the latest available information iXCells Biotechnologies has around 11-50 employees worldwide.
When was iXCells Biotechnologies founded?
iXCells Biotechnologies was founded in 2014
In which industries does iXCells Biotechnologies mainly work?
The company iXCells Biotechnologies has it's main focus in the industries of Biotechnology
Check out some interesting alternative companies to iXCells Biotechnologies
Axol Bioscience
Cambridge, United States
11-50 Employees
2013
Like you, we believe that these more human-relevant advanced in vitro models have the potential to unlock better, safer therapies for neurodegenerative and cardiovascular diseases. Find us on Scientist.com, the world’s leading platform for CROs. With over a decade of experience, we’ve developed the manufacturing capabilities to produce high-quality, functional iPSC-derived cells with excellent consistency. Our leading neuronal cell types include: cortical excitatory neurons, striatal neurons, cortical inhibitory interneurons, microglia, astrocytes, sensory neurons and motor neurons. We also provide high-quality atrial cardiomyocytes and ventricular cardiomyocytes, as well as made-to-order myotubes. We’re offering our world-leading iPSC expertise to researchers who want to build better human disease models with exciting translational potential.
ReproCELL
Yokohama, Japan
51-100 Employees
2003
We provide a unique combination of services and products to power your translational research. With scientists and laboratories on three continents, REPROCELL has the scientific and clinical expertise to better translate your discoveries into therapies. REPROCELL’s portfolio includes an extensive product catalog to support stem cell research and 3D bioengineered tissues, a commercial biorepository of ethically-sourced human tissues, extensive clinical networks across the US and Europe that enable our contract research services in human ex vivo living tissues, and our capability to supply induced pluripotent stem cells (iPSCs) for both research and clinical applications. REPROCELL is also developing novel regenerative medicine therapies to treat neurodegenerative disease, based on its expertise in pluripotent stem cells and mesenchymal stem cells, and is currently conducting clinical trials in Japan for the treatment of spinocerebellar ataxia. Its diagnostic services and clinical research services are offered across labs in Japan, the US, UK, and India.
Newcells Biotech
Newcastle upon Tyne, United Kingdom
1-10 Employees
2015
We are experts in building and applying complex models of human tissues for drug discovery. We are cell biologists, tissue physiologists and assay development scientists focused on building models that balance complexity, functionality, throughput and efficiency to improve the predictive power of in vitro data. We carry out in vitro studies or provide products that enable customers to generate data on efficacy, safety and transport to de-risk discovery and development. Our experts collaborate with customers to design studies to provide data that answer critical questions for pre-clinical drug development. We run the study, provide and interpret the data, or we can supply products and support you in your in-house studies. We aim to contribute to the development of new innovative therapies by delivering services, products and tools based on our models of human tissues that provide data that informs and predicts how these therapies will behave in humans. Newcells mission is to de-risk the decision-making process in drug development by providing physiologically relevant in vitro models that most accurately predict in vivo outcomes. Globally recognised scientific expertise in cell physiology and organoid technology is embedded in all products & services.
NBScience
United Kingdom
51-100 Employees
2002
We offer an extensive selection of specialty products optimized for mesenchymal stem cell populations. Provide your own cells or have us reprogram somatic cells into PSCs. Our stem cell research products have been an integral part of Induced Pluripotent Stem Cells research from the initial discovery of iPSCs to current breakthroughs. Our broad technology platform provides optimized tools for each step of the stem cell workflow: from reprogramming somatic cells to iPSC expansion, validation, and differentiation.
3H Biomedical
Uppsala, Sweden
11-50 Employees
2004
We are a leading supplier of more than 270 different types of primary human cells, animal cells, RNA, DNA and cell-based assays. We are a leading global supplier of more than 270 different types of primary human and animal cell-based products for life science research, drug development, screening of chemicals and biomaterials development. We discover, develop and distribute cell-based products and services for life science research, drug development and tissue engineering. We offer a variety of 'ready-to-use' high-value primary human cells, animal cells, RNA, DNA, cell culture media and cell-based assays. We help scientists be more productive, more competitive and more innovative.
REGROW BIOSCIENCES
Mumbai, India
251-500 Employees
2009
We are dedicated to the research, development and commercialization of cell and stem cell-based products targeting degenerative and life-threatening diseases. Being true to our vision of becoming the world's largest stem cell and organ development factory, we are actively pursuing the next generation stem cell platform which promises to be universal and off-the-shelf. We are continuously innovating and publishing our original research in areas of hematopoietic transplantation, cell potency assays, HLA inventory, inhibitory effects of intraarticular steroid use, gene mutations offering a potential HIV cure and many more. We are hugely invested in the establishment and maintenance of high standards for ethical and corporate governance by partnering with the best of audit firms, certification bodies and independent ethics committees for research and trial purposes. Our clinical trial success speaks about our core expertise in assessment of diseases with unmet clinical need combined with our speed of research translating into safe and effective bed side treatment for patients.